Last viewed: TPTX

Prices are updated after-hours

TPTX

Turning Point Therapeutics, Inc.

TPTX | $76.01 -0.03%

|

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,806,145,795
http://www.tptherapeutics.com
Sec Filling | Patents | 95 employees

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

cancer

add to watch list Paper trade email alert is off

Press-releases

BlossomHill Therapeutics Closes $100 Million Series B Financing
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
TPTX | $76.01 -0.03%

|

Health Technology

| Email alert Add to watchlist
million series therapeutics

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M

|

Health Technology

| -5.75% | O: 0.15% H: 0.59% C: 0.37%
therapeutics

Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | $3.78 0.0% 5.6K

|

| -3.06% | O: -3.19% H: 4.87% C: 4.87%
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -14.68% | O: -4.68% H: 2.46% C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0

|

Health Technology

| 6.54% | O: 0.16% H: 0.47% C: 0.2%
financial results

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K

|

Health Technology

| -43.07% | O: 2.31% H: 10.14% C: 8.87%
granted tumors treatment designation china therapy

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K

|

Health Technology

| -49.21% | O: -1.12% H: 1.1% C: 0.38%

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
Published: 2023-05-18 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K

|

Health Technology

| -59.55% | O: 1.19% H: 0.0% C: -7.17%
review

Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | $290.38 3.83% 220

|

Health Technology

| -33.14% | O: 0.24% H: 0.66% C: 0.66%
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| 7.89% | O: -1.1% H: 0.0% C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M

|

Health Technology

| -19.72% | O: 0.61% H: 0.3% C: 0.24%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -9.75% | O: 0.2% H: 0.13% C: -0.22%
GSK | News | $39.75 1.22% 0.0% 1.6M

|

Health Technology

| 8.4% | O: 0.27% H: 0.6% C: 0.41%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -15.86% | O: 0.38% H: 0.0% C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K

|

Health Technology

| -31.57% | O: 0.38% H: 0.91% C: 0.69%
AMGN | $269.03 2.39% 2.33% 3.4M

|

Health Technology

| 13.73% | O: 0.14% H: 0.28% C: 0.11%
report cancer global therapy growth market

Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
Published: 2022-10-26 (Crawled : 05:00) - biospace.com/
TSVT | $4.52 -2.59% -2.65% 610K

|

| -65.8% | O: 0.37% H: 5.32% C: 4.04%
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -33.63% | O: 0.44% H: 2.9% C: 1.86%
financial

Gastrointestinal Stromal Tumor Market is Expected to Grow at a CAGR of 13.8% by 2032 | DelveInsight
Published: 2022-09-26 (Crawled : 16:00) - prnewswire.com
EXEL | $22.51 0.09% 0.09% 2.3M

|

Health Technology

| 41.43% | O: 0.06% H: 0.98% C: -2.46%
COGT | $6.71 1.51% 1.49% 1.5M

|

Health Technology

| -52.85% | O: -0.71% H: 4.22% C: 3.38%
BPMC | $86.87 -2.28% -2.34% 800K

|

Health Technology

| 34.08% | O: -0.53% H: 2.33% C: -3.22%
expected gastrointestinal market

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Published: 2022-08-17 (Crawled : 13:20) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -34.84% | O: -0.3% H: 1.45% C: 0.88%
acquisition

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-22-046291	4	2022-08-17	2022-08-17	Sell	D	23400	0
0001209191-22-046286	4	2022-08-17	2022-08-17	Sell	D	30000	0
0001209191-22-046284	4	2022-08-17	2022-08-17	Sell	D	8500	0
0001209191-22-046283	4	2022-08-17	2022-08-17	Sell	D	14995	0

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M

|

EGOX | $0.0515 43.06% 30.1% 330M

|

OLB 4 | $0.33 -14.95% 25.53% 840K

|

Technology Services

NVFY | $2.77 31.28% 23.83% 33M

|

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M

|

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M

|

Distribution Services

INSG | $3.03 25.21% 20.13% 330K

|

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K

|

WLGS | $0.59 18.0% 17.9% 2.3M

|

ASNS | $0.828 21.75% 17.86% 18K

|

Last 48 Hours Insiders Buying

RXO P 200000 | $19.37 2.32% 0.0% 1M

|

| 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M

|

| 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K

|

Health Technology

| 22:30
BCDA P 2750 | $0.377 -1.4% 97K

|

Health Technology

| 22:00
RMCF | $3.67 3.38% 3.27% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar